Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023)

Bioventus (BVS) reported Cash from Discontinued Operations of 2169000.0 for Q2 2023, down 70.65% quarter-over-quarter from 1271000.0 in Q4 2022.

Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends

Bioventus has reported Cash from Discontinued Operations for 2 years, with the latest figure at 2169000.0 in Q2 2023.

For the quarter ending Q2 2023, Cash from Discontinued Operations changed N/A year-over-year to 2169000.0; the trailing twelve-month figure through Dec 2023 stood at 2169000.0 (down 1.83% YoY), and the FY2023 full-year result was 2169000.0, down 1.83% from the prior year.
Cash from Discontinued Operations for Q2 2023 stood at 2169000.0, down from 1271000.0 in the prior quarter.
The five-year high for Cash from Discontinued Operations was 859000.0 in Q4 2022, with the low at 2169000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Discontinued Operations (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	-
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	-
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	-
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	Bioventus	571.68 Mn	581.20 Mn	90.77 Mn	-

Download Data